XOMA — XOMA Royalty Share Price
0.000.00%
Last trade - 00:00- $288.54m
- $301.63m
- $28.49m
- 42
- 19
- 76
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 8.78% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.52 | ||
| Price to Tang. Book | 5.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.49% | ||
| Return on Equity | -22.61% | ||
| Operating Margin | -72.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 29.39 | 38.16 | 6.03 | 4.76 | 28.49 | 32.92 | 44.31 | 9.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -13.44 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.
Directors
- James Neal CHM (65)
- Thomas Burns CFO (47)
- W. Denman Van Ness LED (78)
- Heather Franklin IND (54)
- Natasha Hernday IND (49)
- Barbara Kosacz IND (63)
- Joseph Limber IND (68)
- Matthew Perry IND (48)
- Jack Wyszomierski IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 31st, 2011
- Public Since
- June 6th, 1986
- No. of Shareholders
- 179
- No. of Employees
- 13
- Sector
- Media & Publishing
- Industry
- Consumer Cyclicals
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 11,952,889
- Address
- 2200 Powell Street, Suite 310, EMERYVILLE, 94608
- Web
- https://www.xoma.com/
- Phone
- +1 5102047239
- Auditors
- Deloitte & Touche LLP
Upcoming Events for XOMA
XOMA Royalty Corp Annual Shareholders Meeting
XOMA Royalty Corp Annual Shareholders Meeting
Q2 2025 XOMA Royalty Corp Earnings Release
Similar to XOMA
Cumulus Media
NASDAQ Global Market
Educational Development
NASDAQ Global Market
Falcon's Beyond Global
NASDAQ Global Market
Gambling.com
NASDAQ Global Market
Harte Hanks
NASDAQ Global Market
FAQ
What is the XOMA Royalty share price?
As of Today at 06:09 UTC, shares in XOMA Royalty are trading at $24.14. This share price information is delayed by 15 minutes.
How has the XOMA Royalty share price performed this year?
Shares in XOMA Royalty last closed at $24.14 and the price had moved by -4.81% over the past 365 days. In terms of relative price strength the XOMA Royalty share price has underperformed the S&P500 Index by -12.14% over the past year.
What are the analyst and broker recommendations for XOMA Royalty?
The overall consensus recommendation for XOMA Royalty is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the XOMA Royalty dividend yield?
XOMA Royalty does not currently pay a dividend.
Does XOMA Royalty pay a dividend?
XOMA Royalty does not currently pay a dividend.
When does XOMA Royalty next pay dividends?
XOMA Royalty does not currently pay a dividend.
How do I buy XOMA Royalty shares?
To buy shares in XOMA Royalty you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of XOMA Royalty?
As of the previous close price of $24.14, shares in XOMA Royalty had a market capitalisation of $288.54m.
Where are XOMA Royalty shares listed?
Here are the trading details for XOMA Royalty:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: XOMA
What kind of share is XOMA Royalty?
Based on an overall assessment of its quality, value and momentum XOMA Royalty is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a XOMA Royalty share price forecast for 2025?
The analyst consensus target price for shares in XOMA Royalty is $64.67. That is 167.9% above the last closing price of $24.14.
Analysts covering XOMA Royalty currently have a consensus Earnings Per Share (EPS) forecast of -$0.56 for the next financial year.
Find out moreWhat is the trend in the XOMA Royalty share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like XOMA Royalty. Over the past six months, its share price has underperformed the S&P500 Index by -13.78%.
As of the last closing price of $24.14, shares in XOMA Royalty were trading -8.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the XOMA Royalty PE Ratio?
The XOMA Royalty PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of XOMA Royalty?
XOMA Royalty's management team is headed by:
- James Neal - CHM
- Thomas Burns - CFO
- W. Denman Van Ness - LED
- Heather Franklin - IND
- Natasha Hernday - IND
- Barbara Kosacz - IND
- Joseph Limber - IND
- Matthew Perry - IND
- Jack Wyszomierski - IND